Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) fell 0.6% during trading on Wednesday . The stock traded as low as $90.1650 and last traded at $91.47. 639,420 shares traded hands during mid-day trading, an increase of 238% from the average session volume of 189,291 shares. The stock had previously closed at $92.00.
Gemini Therapeutics Trading Down 0.6%
The company’s fifty day simple moving average is $86.99 and its 200 day simple moving average is $68.07. The firm has a market capitalization of $3.96 billion, a P/E ratio of -91.47 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- There Are Different Types of Stock To Invest In
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- How to Invest in Insurance Companies: A Guide
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- Top Stocks Investing in 5G Technology
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
